3/23
08:04 am
zura
Zura Bio (ZURA) had its price target raised by Chardan Capital from $10.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Zura Bio (ZURA) had its price target raised by Chardan Capital from $10.00 to $11.00. They now have a "buy" rating on the stock.
3/20
11:04 am
zura
Zura Bio (ZURA) had its price target lowered by Oppenheimer Holdings, Inc. from $16.00 to $15.00. They now have an "outperform" rating on the stock.
Medium
Report
Zura Bio (ZURA) had its price target lowered by Oppenheimer Holdings, Inc. from $16.00 to $15.00. They now have an "outperform" rating on the stock.
3/19
04:05 pm
zura
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
High
Report
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
3/5
06:30 am
zura
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Medium
Report
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
3/2
06:30 am
zura
Zura Bio to Participate in Upcoming Investor Conferences
Low
Report
Zura Bio to Participate in Upcoming Investor Conferences
2/27
06:30 am
zura
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Low
Report
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2/25
06:30 am
zura
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
High
Report
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
2/24
04:01 pm
zura
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
High
Report
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
2/23
06:30 am
zura
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Medium
Report
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
2/9
07:00 am
zura
Zura Bio (NASDAQ:ZURA) is now covered by analysts at Wedbush. They set an "outperform" rating and a $15.00 price target on the stock.
Medium
Report
Zura Bio (NASDAQ:ZURA) is now covered by analysts at Wedbush. They set an "outperform" rating and a $15.00 price target on the stock.
2/4
06:30 am
zura
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Medium
Report
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
1/21
08:50 am
zura
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
High
Report
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
1/13
04:06 am
zura
Zura Bio (NASDAQ:ZURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Zura Bio (NASDAQ:ZURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
06:30 am
zura
Zura Bio Reports Business Updates and Outlook for 2026
Low
Report
Zura Bio Reports Business Updates and Outlook for 2026